Suchergebnisse - "Yerlikaya, Azmi"

PubPharm (66)

1

Label-free nLC-MS/MS proteomic analysis reveals significant differences in the proteome between colorectal cancer tissues and normal colon mucosa

enthalten in: Medical oncology (Northwood, London, England) | 2023

von Zeren, S. | Seker, S. | Akgün, G. | +2

2

Label-free nLC-MS/MS proteomic analysis reveals significant differences in the proteome between colorectal cancer tissues and normal colon mucosa

enthalten in: Medical oncology | 2023

von Zeren, S. | Seker, S. | Akgün, G. | +2

3

Label-free nLC-MS/MS proteomic analysis reveals significant differences in the proteome between colorectal cancer tissues and normal colon mucosa

enthalten in: Medical oncology | 2023

von Zeren, S. | Seker, S. | Akgün, G. | +2

4

Molecular Pathways, Targeted Therapies, and Proteomic Investigations of Colorectal Cancer

enthalten in: Current molecular medicine | 2023

von Yerlikaya, A. | Zeren, S.

5

Heme-regulated inhibitor : an overlooked eIF2α kinase in cancer investigations

enthalten in: Medical oncology (Northwood, London, England) | 2022

von Yerlikaya, A.

6

Heme-regulated inhibitor: an overlooked eIF2α kinase in cancer investigations

enthalten in: Medical oncology | 2022

von Yerlikaya, A.

7

Heme-regulated inhibitor: an overlooked eIF2α kinase in cancer investigations

enthalten in: Medical oncology | 2022

von Yerlikaya, A.

8

Heme-regulated inhibitor: an overlooked eIF2α kinase in cancer investigations

enthalten in: Medical oncology | 2022

von Yerlikaya, A.

9

Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line

enthalten in: Medical oncology (Northwood, London, England) | 2021

von Kanbur, E. | Baykal, A. | Yerlikaya, A.

10

Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line

enthalten in: Medical oncology | 2021

von Kanbur, E. | Baykal, A. | Yerlikaya, A.

1
2
3
4
5
6
7
Nächster »
[7]